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Abstract
Background: Evidence suggests that current treatments cannot fully alleviate the burden of disease associated
with depression but that prevention approaches offer a promising opportunity to further reduce this burden.
Adolescence is a critical period in the development of mental illness, and final school examinations are a significant
and nearly universal stressor that may act as a trigger for mental health difficulties such as depression. The aim of
the present trial is to investigate the impact of SPARX-R, an online, gamified intervention based on cognitive
behavioural principles, on the prevention of depression in secondary school students before their final
examinations.
Methods/Design: Government, independent and Catholic secondary schools in New South Wales, Australia, will be
recruited to participate in the trial. All students enrolled in their final year of high school (year 12) in participating
schools will be invited to participate. To account for possible attrition, the target sample size was set at 1600
participants across 30 schools. Participating schools will be cluster randomised at the school level to receive either
SPARX-R or lifeSTYLE, an attention-controlled placebo comparator. The control intervention is an online program
aimed at maintaining a healthy lifestyle. The primary outcome will be symptoms of depression, and secondary
outcomes will include symptoms of anxiety, suicidal ideation and behaviours, stigma and academic performance.
Additional measures of cost-effectiveness, as well as process variables (e.g., adherence, acceptability) and potential
predictors of response to treatment, will be collected. Consenting parents will be invited to complete measures
regarding their own mental health and expectations for their child. Assessments will be conducted pre- and
post-intervention and at 6- and 18-month follow-up. Primary analyses will compare changes in levels of depressive
symptomatology for the intervention group relative to the attention control condition using mixed-effects model
repeated-measures analyses to account for clustering within schools.
Discussion: This is the first trial of a universal depression prevention intervention delivered to school students in
advance of a specific, significant stressor. If found to be effective, this program may offer schools a new approach to
preparing students for their final year of schooling.
Trial registration: Australian New Zealand Clinical Trials Registry identifier: ACTRN12614000316606. Registered 25
March 2014.
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Background
By 2030, depression is predicted to be the second leading
cause of disease burden worldwide [1]. Currently, in young
people aged 10–24 years, it carries the greatest burden of
disease [2]. Andrews et al. [3] calculated that only 13 % of
this burden can be averted by available treatments and that,
even with improved coverage, clinician competence and
adherence, only 36 % of the burden of depression could
potentially be alleviated using current knowledge and ther-
apies. Indeed, Australian national data on service provision
and access to treatment have demonstrated a considerable
improvement over the previous two decades, with no
discernible effect on prevalence, which, if anything, has in-
creased [4]. This leaves the majority of the burden of major
depression unaddressed. Further, relapse and recurrence of
depression are frequent. More than 80 % of individuals with
major depressive disorder (MDD) experience multiple epi-
sodes [5], with each additional episode predicting a greater
likelihood of future recurrence [6], even after successful
treatment [7, 8]. Given the potential chronicity of this dis-
order, intervening before the onset of a first episode repre-
sents a unique opportunity to change a lifelong trajectory
of depression. A recent meta-analysis of 32 randomised
controlled trials indicated a 21 % reduction in incidence of
depression following the implementation of prevention
programs [9]. Although there are some limitations to this
analysis, prevention approaches represent a potential crit-
ical pathway to decreasing depression rates and the associ-
ated burden of this disorder.
Despite evidence indicating the overall effectiveness of
prevention of depression [9], it remains unclear exactly
which of the various prevention approaches is superior,
for whom prevention programs are most effective, and
under what circumstances the programs should be deliv-
ered. Universal prevention approaches are applied to whole
populations, without regard to individual risk, whereas
selective and indicated approaches target high-risk individ-
uals on the basis of the presence of existing risk factors and
subthreshold symptoms, respectively. Reviews in the litera-
ture have generally found larger effect sizes for targeted
interventions. For example, data derived from a systematic
review of school-based depression prevention programs
found indicated programs to be the most effective [10]. Six
of ten indicated trials demonstrated significant differences
between the intervention and control conditions at post-
test, with effect sizes ranging from 0.25 to 1.35. In con-
trast, only 9 of 23 universal interventions found
significant effects over the control condition, though
the range of effect sizes in these trials was similar to
those in the indicated trials (d = 0.30–1.40). It should
be noted, however, that it is easier to demonstrate suc-
cess in indicated programs because individuals are
selected on the basis of symptoms, meaning that there
is greater opportunity for change (typically symptom
reduction) to occur [11]. However, a key problem with
the indicated approach in mental health is that indi-
viduals who are not yet symptomatic are not targeted
in the intervention (see [12]). This means that individ-
uals who may ultimately progress to develop symptoms
will be missed. In contrast, by definition, universal preven-
tion approaches provide greater scope and catchment of
individuals who may be on the trajectory towards develop-
ing depression.
From an empirical perspective, whereas three recent uni-
versal prevention trials failed to find significant effects [13–
15], a Cochrane review of 39 targeted (including both se-
lective and indicated) and 31 universal psychological and
educational prevention interventions for young people
found evidence to support both targeted (number needed
to treat [NNT] = 14) and universal programs (NNT= 8)
[16]. With regard to diagnosis of depressive disorders,
targeted interventions reduced diagnoses post-
intervention (risk difference = −0.07) and at 3–9-month
follow-up (risk difference = −0.06) relative to no inter-
vention. Universal programs were also found to be ef-
fective immediately following the intervention and 3–9
months later (risk difference = −0.12 and −0.19, respect-
ively). Similar results were found for depressive symptoms,
with both targeted and universal interventions demonstrat-
ing evidence of efficacy post-intervention (standardised
mean difference = −0.31 and −0.10, respectively) and at
follow-up (standardised mean difference = −0.22 and −0.09,
respectively).
Despite mixed evidence, the finding that universal pro-
grams may indeed be effective is important, given that
they may also be easier to implement and are less stig-
matising [17, 18]. Universal programs also have the
added advantage of providing a foundation of skills upon
which subsequent targeted programs can build [17].
Given that there is some support for universal programs
but that this approach may not be effective in all cir-
cumstances, there is a clear case for further investigation
of this kind of prevention. It is important, however, to
determine the specific parameters within which universal
prevention interventions are most likely to succeed. One
potentially useful approach is to conduct universal inter-
ventions in advance of a stressor that is experienced uni-
versally and predictably.
Rates of depression begin to increase at 12–13 years of
age, but the growth in incidence is continuous, with new
cases of depression emerging at a similar rate through-
out adolescence [18]. In determining the point at which
a preventive intervention might be optimally delivered, it
is notable that stressful life events act as predictors and
candidate causal factors in the development of depres-
sion [19]. Final examinations represent a significant stres-
sor for most adolescents. More specifically, in cultures
where significant emphasis is placed on university
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entrance examinations in the final year of school, students
tend to spend much more time doing schoolwork and less
time in discretionary activities and to have more negative
affective states across daily activities and higher rates of
depression, relative to cultures without this focus on ex-
aminations [20]. Indeed, Kouzma and Kennedy [21] noted
that the main sources of stress reported by final-year stu-
dents in Australia were school-related. Amongst these
stressors, examinations and academic outcomes were
endorsed most strongly (see also [22–24]). Further, more
than 40 % of year 12 students in Australia reported symp-
toms of depression, anxiety and stress that fall outside
normal ranges [25]. In extreme cases, examination stress
has even been linked to suicidal ideation, behaviour and
completion [26, 27]. Because stress can lead to social and
emotional difficulties, which can then interfere with aca-
demic achievement, programs that help students to man-
age stress before examinations may be beneficial, in terms
of both improving mental health and enhancing academic
performance [28].
To date, the potential for prevention has not been
examined in the context of school-based stressors. How-
ever, researchers in one study examined the effect of a
prevention program in a group of medical students in
the United States [29]. Participants (mean age 27.6 years)
were allocated to receive either MoodGYM, an online
cognitive behavioural intervention, or an attention con-
trol program before their first-year internship. Com-
pared with the control group, interns who completed
the intervention were almost four times less likely to
experience an episode of depression during their intern-
ship (13.0 % vs. 34.8 %). This finding suggests that pre-
vention programs delivered before an anticipated period
of increased stress may protect against the development
of depression.
In terms of the most effective approaches to preven-
tion interventions, one of the key factors to consider is
the therapeutic orientation of the program. Hetrick and
colleagues [30] recently conducted an exploratory meta-
analysis, specifically examining program content, based on
the trial data included in Merry et al.’s 2011 Cochrane
review [16]. Of the 50 intervention arms examined, 38 were
classified as based purely on cognitive behavioural therapy
(CBT), 4 reported data on interpersonal psychotherapy
(IPT) interventions and 8 were classified as ‘other’ in orien-
tation. Results indicate not only that CBT is the most
studied type of intervention for depression prevention
but also that there is evidence to support its effective-
ness in reducing the risk of developing a depressive
disorder and reducing depressive symptoms both post-
intervention and at follow-up. Mixed evidence was
found for IPT, and other interventions were not found
to be effective. The majority of programs in the review
were delivered face-to-face to groups of adolescents in
school settings, though the authors acknowledged that
online delivery of programs is becoming increasingly
popular.
With regard to setting, schools are an ideal location to
deliver mental health interventions, not only because
young people spend more time in these institutions than
any other, but also because of the integral role schools
play in students’ social, academic, cognitive, emotional
and behavioural development [31]. Further, the provision
of mental health interventions in schools (in contrast to
providing students access to these interventions inde-
pendently) necessarily increases uptake and adherence
[32]. From cost-effectiveness, engagement and delivery
perspectives, online technology is an advantageous means
by which to deliver programs to students en masse [4].
Further, automated online programs guarantee fidelity
because the information cannot be distorted or adapted
during implementation of the program, nor does it rely on
personal delivery [33]. These programs also have the
benefit of avoiding a number of practical difficulties,
such as the need for expensive face-to-face input from
health professionals [34] or time-consuming teacher
training (see, e.g., [14]). Therefore, delivering a univer-
sal, school-based CBT program to adolescents before a
major stressor has the potential to prevent the onset
of depression.
The present SPIRIT-compliant [35] protocol (see Table 1)
describes the methodology for a cluster randomised con-
trolled trial designed to test the effectiveness of SPARX-R,
an online, CBT-based, gamified intervention designed to
prevent the development of depression in students’ final
year of secondary studies (known as the Higher School
Certificate [HSC]). SPARX was designed as a treatment
intervention for depression. For the purpose of the current
study, SPARX will be revised for use as a preventive inter-
vention, known as SPARX-R. SPARX has been shown to be
non-inferior to treatment as usual (primarily individual
face-to-face therapy) in depressed help-seeking adolescents
[36], for whom use of the program resulted in clinically
significant reductions in depressive symptoms. An online
active control program (lifeSTYLE) focused on maintaining
a healthy lifestyle will serve as an attention-controlled com-
parator. In addition to evaluating the relative impact on
depressive symptoms, in the trial we will also explore the
impact of SPARX-R on a range of secondary outcome vari-
ables, including academic performance, anxiety and suicidal
ideation, as well as parental, process and cost-effectiveness
variables.
A secondary aim of the trial is to determine the role of
individual differences in response to both stress and the
intervention, as these are likely to impact outcomes of
interest. These variables (which may either increase vulner-
ability or act as protective factors) include family history of
depression, social support [37], mastery [38], hopelessness
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[39], ruminative response style [40], neuroticism [41], be-
longingness and burdensomeness [42], disturbances in the
sleep–wake cycle (see [43]), expressed emotion [44] and
cortisol levels [45]. In addition to these factors, genetics are
implicated in the onset of depression, both alone and in
combination with environmental variables (see, e.g., [46]).
Therefore, we also plan to examine a range of genetic
markers to determine if, and in what way, genetics may
interact with outcomes. Collection of cortisol and gen-
etic data will be subject to approval of relevant govern-
ing ethics bodies.
Hypotheses
With regard to the primary outcome measure, we pre-
dict that, relative to participants in the attention control
condition, students who are assigned to the SPARX-R
condition will demonstrate lower levels of depressive
symptoms immediately following the intervention. We
also anticipate that depressive symptoms for SPARX-R
participants will be lower than those in the lifeSTYLE
group at 6- and 18-month follow-up. For secondary out-
comes, we expect that, relative to the lifeSTYLE group,
participants in the SPARX-R group will perform signifi-
cantly better in their HSC and demonstrate reduced
anxiety, suicidal ideation and/or behaviour and stigma
following the intervention and at follow-up. We antici-
pate that SPARX-R will have an effect on the parents of
students allocated to this group, reducing their own
symptom levels at 6 months, relative to parents of
students in the attention control group. Finally, we pre-
dict that SPARX-R will be more cost-effective than life-
STYLE, owing to fewer days out of role (e.g., studying,
working), better quality of life and less use of health
services at 6- and 18-month follow-up.
For those in the SPARX-R group, we predict that a posi-
tive response to the prevention program will be associated
Table 1 Items from the World Health Organisation dataset
Data category Information
Primary registry and trial identifying number Australian New Zealand Clinical Trials Registry identifier: ACTRN12614000316606
Date of registration in primary registry 25 March 2014
Secondary identifying number U1111-1154-5917
Sources of monetary or material support National Health and Medical Research Council
Primary sponsor Black Dog Institute, University of New South Wales
Secondary sponsors
Contact for public queries YP, HC
Contact for scientific queries YP, HC
Public title Trial for the Prevention of Depression (TriPoD)
Scientific title Inoculating final-year high school students: effectiveness of a universal prevention program for
depression in adolescence
Country of recruitment Australia
Health conditions or problems studied Depression, anxiety and suicidal ideation and behaviour
Interventions Active comparator: SPARX-R, an online, interactive game based on the principles of cognitive
behavioural therapy designed to prevent depression in young people
Placebo comparator: lifeSTYLE, an online program providing interactive content on a range
of general health and well-being topics
Key inclusion and exclusion criteria Inclusion criteria: male and female final-year secondary school students at participating schools
Exclusion criteria: none
Study type Study type: interventional
Allocation: randomised
Intervention model: parallel assignment
Primary purpose: prevention
Date of first enrolment February 2015
Target sample size 1600
Recruitment status Recruiting
Primary outcome Symptom levels of depression
Key secondary outcomes Symptoms of anxiety, academic performance, suicidal ideation and behaviour, and stigma
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with the following variables at baseline: absence of family
history of depression, high social support, high mastery,
low rumination, low neuroticism and/or negative affect,
low hopelessness, low thwarted belongingness, low bur-
densomeness, low sleep disturbance, unimpaired sleep–
wake patterns, low expressed emotion, low cortisol levels
and lack of genetic vulnerability factors.
Methods/Design
Trial design
This study is a cluster randomised controlled superiority
trial with two parallel arms, consisting of an experimen-
tal condition and an attention-matched control condi-
tion. We will employ an adaptive design, such that
accumulating data will be used to decide if or how to
modify the study as it continues. To facilitate this design
and to stagger recruitment, the trial will take place in
two stages across consecutive years, with each stage be-
ginning at the start of the academic calendar (February
2015 and February 2016). The intervention phase will
last 5 weeks with a follow-up period of 18 months. Re-
sults from the 2015 cohort will be subject to an interim
analysis to determine preliminary effects and determine
whether any modifications are required in the conduct
of the trial in 2016. Feasibility of continuation will also
be assessed at this stage in terms of student and teacher
acceptability of the intervention and any implementation
issues that may arise during the first year of the trial.
Ethical approval
This trial has received ethical approval from the New
South Wales Department of Education and Training,
the University of New South Wales, the University of
Melbourne, Australian National University and South-
ern Adelaide Clinical Human Research Ethics Commit-
tees. Recruitment of schools will not be conducted
until all local approval has been obtained. Any ad-
verse events will be reported to the director of the
Black Dog Institute and to the relevant human research
ethics committees.
Setting
The trial will be conducted in government, independent
and Catholic secondary schools in New South Wales,
Australia. Government schools in New South Wales are
classified as either comprehensive or selective. Compre-
hensive schools accept enrolments of all students in the
surrounding area, whereas selective high schools use an
entry examination to enrol students with superior aca-
demic ability. The first stage of the trial will be con-
ducted in government schools in metropolitan Sydney.
Ethical approval to collect biological data in government
schools was not granted. Therefore, measures of cortisol
and genetic vulnerability will be collected only in the 2016
cohort (which we expect will comprise primarily inde-
pendent and Catholic schools), pending ethical approval.
The 2015 cohort will comprise students from selective
government secondary schools. Although study-related
stress is a widely experienced phenomenon, academically
gifted students may be particularly at risk of experien-
cing stress-related mental health difficulties during the
final examination period, given the high rates of perfec-
tionism in this group, as well as the pressure to succeed
from parents, schools, the media and students them-
selves (see, e.g., [47]). Perfectionism has been shown to
be a strong predictor of prospective stress in the context
of an academically demanding end-of-semester period
[48]. Further, the increased academic workload and con-
siderable number of hours spent studying by students in
a demanding education program is likely to compound
this pressure and act as an additional source of stress
[49]. Indeed, high-stakes examinations can lead to a
range of negative outcomes in high-achieving students,
including anxiety, depression, school absence, helpless-
ness and ulcer [21, 50]. Thus, the characteristics of stu-
dents in selective high schools make these schools a
particularly relevant target for the present trial. It should
be noted that some government schools have both se-
lective and comprehensive streams. All students at these
partially selective high schools will be eligible to partici-
pate; however, streaming status will be recorded, and
school type will be accounted for in analyses.
Participants
All adolescents enrolled in their final year of high school
in participating schools will be invited to participate.
The age range at baseline is 16–18 years. Owing to the
universal nature of the study, there are no exclusion cri-
teria. Students are free to receive additional support
from health care professionals while participating in the
trial, and this will be assessed and accounted for in sec-
ondary analyses.
Recruitment
A flowchart outlining recruitment, randomisation and
participation in this trial is provided in Fig. 1.
Thirty secondary schools across the state of New
South Wales will be recruited to participate in the
trial. School principals will be notified about the trial
in writing and invited to allow their schools to partici-
pate. Research personnel may also meet with princi-
pals and/or teachers in person to provide information
about the study and answer any questions. Once prin-
cipals formally agree to their schools’ participating in
the trial, parents and students will be informed about
the trial.
Assignment to the intervention arm will occur at the
school level. All students will complete the intervention,
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which will be integrated into the curriculum at each par-
ticipating school. Consent will be sought from students
and parents only with regard to the research component
of the interventions (i.e., the completion of outcome mea-
sures and collection of other data). To maximise consent
rates, information and consent forms will be distributed
during the final term of the preceding school year. School
administrators or class teachers will be provided with
parental and student information and consent forms to
pass on to all students enrolled in Year 12 the following
academic year. Alternatively, schools may prefer to pro-
vide parents and students with consent forms at parent
information sessions or to email parents the consent
forms directly. Parents will be asked to either return a
hard copy of the signed consent form to the school via
their child or send a scanned or photographed copy via
email. Parents will also be invited to participate in a
parent survey by providing their email address and con-
sent in an optional section of the consent form. In-
formed consent will be obtained from each participant,
and students will be asked to return their signed consent
forms to the school. In addition to participating in the
study, students will have the option to provide consent for
their school to provide their final examination results to
the trial researchers and for the Trial for the Prevention of
Depression (TriPoD) investigators to contact them in the
Fig. 1 Planned flow of participants through the Trial for Prevention of Depression cluster randomised controlled trial
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future to inform them about any follow-up studies that
may be conducted.
Using student email addresses provided by the schools,
all students will be emailed a unique identification code
before commencing the trial, which will allow them to
register to access their allocated program via an online
platform. This secure platform was designed specifically
to facilitate the delivery of online interventions in a re-
search context and can be configured to meet the needs
of specific trials. For TriPoD, both of the interventions,
as well as the research questionnaires, can be accessed
through this platform. Those students without parental
or personal consent will still register and access the pro-
gram through the research platform; however, only those
with consent will be given access to the research ques-
tionnaires as well. Students who do not have consent
will complete an innocuous filler task while their peers
are completing the research questionnaires.
Sample size
Depression has an estimated annual prevalence of 8.3 %
in adolescents [12], and between 8 % and 20 % of young
people in community samples develop depression over
an 18-month period [51–53]. On the basis of the age of
the current sample, together with the timing of the
intervention (before a major, universal stressor), we ex-
pect that onset rates will be high (up to 15 %). Calcula-
tions of required sample size for the primary outcome
measure were based on detecting a post-intervention
effect size of 0.20 in combined analyses of data collected
from 2015 and planned 2016 cohorts. This estimate is
based on previous depression prevention research using
an online intervention [54]. Although the expected effect
is small, it reflects the universal nature of this interven-
tion. Power was set at 0.80, α = 0.05 (two-tailed) and a
correlation of 0.5 assumed between baseline and end-
point scores. To allow for possible clustering effects (i.e.,
participants from the same school having characteristics
and outcomes more alike than between schools), a de-
sign effect [55] was calculated assuming an intraclass
correlation coefficient (ICC) of 0.02 and an average class
size of 25. The estimate of the ICC was derived from a
previous Australian school-based study that found a non-
significant ICC of 0.02 [54]. The estimated sample size
was 1166. The target size sample size was set at 1600, or
800 students per condition, to accommodate an attrition
rate of approximately 20 % (see [56]). This translates to
approximately 50 students (or 2 classes) per school in 30
schools. An interim analysis of students in the 2015 co-
hort will involve approximately 300 students per arm.
Under the assumptions outlined above, there will be 80 %
power to detect an effect size of 0.40 standard deviations
between groups.
Randomisation
Each participating school (cluster) will be randomised to
complete the SPARX-R or lifeSTYLE program. School-
level randomisation will be used to avoid contamination
between conditions, for the ecological validity of provid-
ing the intervention at the cluster level and for practical
convenience. A statistician not involved in the implemen-
tation of the trial will randomly allocate schools using the
allocation sequence outlined below. The identity of schools
will be concealed from the statistician during this process.
Randomisation in cluster randomised trials is prob-
lematic because the number of clusters involved is usu-
ally relatively small. In large, individually randomised
trials, balance in the makeup of each arm is achieved as
a function of the numbers involved. Balance between
arms can be achieved by stratification or minimisation
[57]. Stratification can accommodate only a limited num-
ber of balancing variables, and minimisation is based on
incremental assignment of participants to groups. In
TriPoD, the number of potentially relevant variables to be
balanced between arms is quite large (e.g., sex, number of
enrolled students, Index of Community Socio-Educational
Advantage school index, language background other than
English), and all available sites will be enumerated before
commencement of the trial. Achieving approximately
equal numbers of participants in each arm is also an aim
of the allocation design, as this will determine the study’s
power in the absence of substantial clustering effects.
Accordingly, this attribute of each school will be used not
to estimate the degree of balance, but rather to screen
potential grouping after balanced combinations have been
selected.
We will use the method developed and implemented
by Carter and Hood [58] to ensure balance between
intervention arms. This enumerates all possible divisions
of the available schools into two groups and calculates a
balance index [59] for each of these groupings. The 10
most balanced groupings will be retained after excluding
any grouping resulting in a deviation of more than 10 %
in predicted individual participant sample size between
inventions. The allocation schedule will be selected at
random from the groupings retained.
Interventions
SPARX-R
The experimental intervention in this trial is SPARX-R,
a revised version of SPARX, which was originally devel-
oped using an unguided, interactive fantasy game format
that provides CBT skills to treat mild to moderate symp-
toms of depression in help-seeking adolescents. SPARX
resulted in a decline in symptoms of depression and was
shown to be non-inferior to treatment as usual, which con-
sisted primarily of face-to-face therapy with a counsellor,
general practitioner or clinical psychologist [36]. In this
Perry et al. Trials  (2015) 16:451 Page 7 of 17
trial, response rates and treatment satisfaction did not differ
between groups, nor did symptoms of depression, anxiety,
hopelessness or quality of life, at post-intervention and 3-
month follow-up. Further, remission rates were higher in
the SPARX group. A pragmatic randomised controlled trial
in a group of young people excluded from mainstream edu-
cation also found SPARX to be superior to waitlist control
with regard to reducing symptoms of depression [60]. Atti-
tudes towards SPARX have been predominantly positive,
with youth workers in New Zealand, young people alien-
ated from mainstream schooling and rural Australian youth
endorsing the program as a viable alternative to traditional
therapeutic interventions [61–63]. Indeed, students in alter-
native education felt that SPARX should be offered to all
adolescents in courses like their own, as they felt that pro-
viding the intervention at an indicated or targeted level
might be stigmatising and that all could benefit from the
lessons provided [64].
SPARX-R uses the same content as SPARX but is framed
as a preventive intervention. For example, in the original
version, participants are told that ‘SPARX was made to help
young people who feel down or depressed’. In contrast, the
SPARX-R introduction informs participants that ‘this
version of SPARX was made to help young people who are
having hassles and feeling down, stressed or angry a lot of
the time. Even if you are doing fine, SPARX-R can help
strengthen your skills for dealing with problems when they
do come along’. Participants using SPARX-R choose and
personalise an avatar and are led through the program by a
virtual guide character who provides context and instruc-
tion and relates the content of the program to the partici-
pant’s real-life experiences. The participant navigates
through a series of challenges and obstacles within a fantasy
world that has been overrun by gloomy, negative, automatic
thoughts. The student’s mission is to restore balance in the
game world. The program has seven modules (levels), each
of which takes approximately 20–30 minutes to complete.
The modules cover the following topics: (1) finding hope,
(2) being active, (3) dealing with strong emotions, (4) over-
coming problems, (5) recognising unhelpful thoughts, (6)
challenging unhelpful thoughts and (7) bringing it all
together. SPARX-R will be delivered to participants via the
internet on desktop computers in school classrooms.
lifeSTYLE
lifeSTYLE is an adaptation of an interactive, online pro-
gram that was originally developed as a control interven-
tion for a previous trial targeting adults with suicidal
thoughts [65]. The format and structure of the program
have been retained, but the content has been adapted to
suit the needs of a younger group. The aim of the inter-
vention is to provide an engaging and useful resource
for young people that matches the intervention in terms
of duration and attention but without providing any
strategies or techniques to prevent or manage mental
health difficulties. The program also includes seven mod-
ules (approximately 25 minutes each) and covers the
following topics: (1) independence, (2) participating in
your community, (3) work skills, (4) mobile phone safety
and hygiene, (5) healthy skin, (6) sustainable eating and
(7) maintaining a healthy home environment. Each mod-
ule includes information about the specified topic as well
as interactive activities such as quizzes, myth busters,
videos and scenarios that students can reflect on and re-
spond to. As with SPARX-R, the intervention is delivered
to students in school classrooms via the online platform
on desktop computers.
Procedures
Immediately before the baseline assessment, during an allo-
cated class period, school teachers will provide students
with a URL that will take them to the trial registration page.
Students will use their unique identification code to register
at this page and set up a personal password. Students will
also be required to provide a personal email address and
mobile telephone number so that they can be contacted
during the follow-up period after they have left school.
Students with parental and personal consent will
complete questionnaires on three occasions during
class time (pre-intervention, post-intervention and 6-
month follow-up), as well as an additional 18-month
follow-up questionnaire once they have graduated from
secondary school. The timing of assessments was de-
signed such that the 6-month follow-up will be con-
ducted just before the trial HSC examination period,
one of two major examination periods during the final
year of school.
All assessments will be conducted via the online plat-
form. Teachers will direct students to log on to the
platform during the first three assessments, and partici-
pants will be emailed a link to log on directly from their
personal computer on the final assessment occasion.
All students will complete their allocated intervention
(SPARX-R or lifeSTYLE) over the course of approxi-
mately 5–7 weeks in school via the online platform.
Schools will timetable the intervention sessions to fit in
with their respective schedules, but they will be advised
to space sessions out so that students have sufficient
time to reflect on the material presented in each mod-
ule. On each assessment occasion, students who do not
complete their assessments during the scheduled class
time (owing to absence or other conflicting duties) will
be asked to complete the questionnaires in their own
time. A reminder email will be sent 1 week after the
scheduled assessment, and a final reminder will be sent
another week later to any student who still has not
completed the scheduled assessment. Trial researchers
will monitor completion of assessments and will remain
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in close contact with participating schools to ensure
that school staff encourage assessment and intervention
completion by all participating students. Students will
no longer be able to access or complete assessments
1 month after their school’s scheduled assessment date.
Measures
The administration schedule for each of the assessment
measures described below is provided in Table 2.
Primary outcome measure
Major Depression Inventory
The Major Depression Inventory is a 12-item self-report
measure of depressive symptoms [66]. The items of the
MDI evaluate the presence and duration of depressive
symptoms according to criteria of both the International
Classification of Diseases, 10th revision (ICD-10), and
the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition (DSM-IV) [67]. Participants rate the
degree to which they have experienced each of the 10
symptoms over the preceding 2 weeks on a 6-point
scale, ranging from 0 (at no time) to 5 (all of the time).
The MDI has acceptable sensitivity and specificity for
the diagnosis of depression according to the ICD-10 and
DSM-IV [66]. To accord with DSM criteria and evaluate
functional impairment, we included an extra question
on the MDI asking participants to indicate (on the same
scale) the degree to which their depressive symptoms in-
terfered with activities of daily living over the previous
2-week period.
Secondary outcome measures
Screen for lifetime presence of a major depressive episode
or manic episode
Screening questions from the Structured Clinical Inter-
view for DSM-IV disorders–Mood module [68] were
included to provide an indication of a lifetime presence
of a major depressive episode or manic episode. Mood,
anhedonia, mania and irritability are assessed, and par-
ticipants respond by answering ‘yes’ or ‘no’ to whether
they have ever had prolonged experiences of each
symptom (2 weeks for mood and anhedonia, 1 week for
mania and irritability).
Australian Tertiary Admission Rank
Participants’ academic performance will be assessed by
means of their estimated Australian Tertiary Admission
Rank (ATAR) scores. With students’ consent, schools
will provide researchers with students’ HSC results, from
which an estimate of each student’s ATAR score will be
calculated using a standard online ATAR calculator.
Spence Children’s Anxiety Scale
The Spence Children’s Anxiety Scale is a 44-item meas-
ure comprising 6 subscales. The scale was designed to
measure the severity of children’s and adolescents’ anx-
iety symptoms based broadly on DSM-IV criteria for
anxiety disorders [69]. Respondents rate the degree to
which they experience each symptom on a 4-point fre-
quency scale, ranging from 0 (never) to 3 (always). Only
items on the Social Phobia and Generalised Anxiety
subscales will be administered in the present study. The
scale has demonstrated high internal consistency and
satisfactory test-retest reliability [18]. It was also reported
to show both convergent [70] and divergent [18] validity.
Youth Risk Behavior Survey
The Youth Risk Behavior Survey (YRBS) was designed to
assess health risk behaviours among school students in
years 9–12. For the purposes of the present study, the
YRBS will be abbreviated to three items concerning sui-
cidal thoughts, plans and attempts over the preceding
month, for which participants will provide a yes-or-no
answer. Endorsement of any of these items will trigger
the trial’s participant risk management protocol (see
below). Studies have shown that the suicidality items
demonstrate both substantial reliability [71] and good
convergent and divergent validity in high school samples
[72].
Depression Stigma Scale
The Depression Stigma Scale (DSS) is an 18-item meas-
ure that assesses personal and perceived stigma towards
depression. In the present study, only the nine-item per-
sonal stigma subscale will be used. These items require
participants to rate how strongly they personally agree
with a statement about depression (e.g., ‘people with
depression are unpredictable’) on a 5-point Likert scale
ranging from 0 (strongly disagree) to 4 (strongly agree).
The sum of each of the items yields a total stigma score,
where higher scores indicate greater stigma. The per-
sonal stigma subscale of the DSS has been shown to
have moderate internal consistency in an adolescent
sample [73, 74].
Predictor variables
Schuster Social Support Scale
The Schuster Social Support Scale is a 15-item measure
of social support used to examine an individual’s social
relationships with others and the associated impact on
their emotional functioning. Each item is rated on a 4-
point scale from 0 (not at all) through to 3 (all the time).
The scale has demonstrated acceptable reliability coeffi-
cients [75]. For the present study, 10 items from 2 sub-
scales which measure support from friends and family
will be used.
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Pearlin Mastery Scale
The Pearlin Mastery Scale is a widely used instrument
designed to measure participants’ perceived sense of
mastery over life outcomes. Respondents are required to
rate how strongly they agree or disagree with a list of
seven statements on a scale from 1 (strongly disagree) to
4 (strongly agree). The total scores range from 7 to 28,
with higher ratings indicative of a higher level of self-
mastery, or control of the forces that affect their lives.
The scale has shown good construct and predictive val-
idity (see [76]) and good internal consistency [77].
Ruminative Response Scale–short version
The Ruminative Response Scale–short version is a 10-
item, self-report questionnaire in which participants
reflect upon the causes, meanings and consequences of
their negative mood states. Participants are asked to rate
how well the statements reflect what they generally do
Table 2 Assessment administration schedule
Assessment Construct Baseline Post-intervention 6 months 18 months Other
Primary outcome
MDI Depression symptoms X X X X
Secondary outcomes
ATAR Academic performance Collected via schools after final
examination results are released
SCAS Anxiety symptoms X X X X
YRBS Suicidal ideation X X X X
DSS-P Personal stigma X X X X
Predictor variables
SSSS Social support X
PMS Mastery X X X
RRS Rumination X X X
PID-5-BF Personality traits X
HPLS-Brief Hopelessness X
INQ Belongingness/burdensomeness X
ACSS Capability X
ISI Sleep disturbance X
MEQr Sleep–wake patterns X
PS/PC Expressed emotion X
Cost-effectiveness variables
TiC-P Service use X X
Questionnaire Days out of role X X
AQoL Quality of life X X
Process variables
Questionnaire Expectation of success X
Intervention data Adherence Collected automatically via SPARX-R
and lifeSTYLE
Questionnaire Acceptability, usability X
IIAM Reasons for dropout X
Parent outcomes
PHQ-9 Depression X X
GAD-7 Anxiety X X
ACSS Acquired Capability for Suicide Scale; AQoL Assessment of Quality of Life; ATAR Australian Tertiary Admission Rank; DSS-P Depression Stigma Scale–Personal
Stigma subscale; GAD-7 Generalized Anxiety Disorder 7-item scale; HPLS Hopelessness Scale for Children; IIAM Internet Intervention Adherence Measure;
INQ Interpersonal Needs Questionnaire; ISI Insomnia Severity Index; MDI Major Depression Inventory; MEQr Reduced version of the Morningness Eveningness Question-
naire PS/PC Perceived Sensitivity/Perceived Criticism scale; PHQ-9 Patient Health Questionnaire-9; PID-5-BF Personality Inventory for DSM-5; Brief Form; PMS
Pearlin Mastery Scale; RRS Ruminative Response Scale; SCAS Spence Children’s Anxiety Scale; SSSS Schuster Social Support Scale; TiC-P Trimbos/iMTA ques-
tionnaire for Costs associated with Psychiatric illness; YRBS Youth Risk Behavior Survey
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when feeling sad, blue or depressed on a 4-point Likert
scale from 1 (almost never) to 4 (almost always). Higher
scores indicate a greater degree of rumination about
negative feelings and experiences. The short version has
been shown to be a reliable measure of rumination that
is less confounded by depression than the original ver-
sion [78]. The scale has good construct validity [79] and
convergent and discriminant validity [80]. It also has
adequate internal consistency (α = 0.77 and 0.72 for the
brooding and reflection subscales, respectively) and test-
retest stability [78].
Personality Inventory for DSM-5 Brief
The Personality Inventory for DSM-5, Brief Form (PID-
5-BF), is a 25-item self-rated personality trait assess-
ment scale developed by the American Psychiatric
Association’s Personality Disorders Work Group [81]. It
measures the five proposed DSM-5 personality trait do-
mains, including negative affect, detachment, antagon-
ism, disinhibition and psychoticism, with each domain
composed of five items. The scale asks respondents to
rate how well the item describes themselves generally
on a 4-point scale from 0 (very false or often false) to 3
(very true or often true). Overall scores range from 0 to
75, with higher scores indicating greater personality
dysfunction. The scale has demonstrated good conver-
gent validity with other widely used personality mea-
sures [82]. Further, though originally developed for
adults, the PID-5 was also shown to be a reliable tool for
measuring personality pathology within adolescent popu-
lations, with good reliability reported for personality trait
domains and strong construct validity [83].
Hopelessness Scale for Children–Brief
The Hopelessness Scale for Children (HPLS)–Brief is a 5-
item measure adapted from the HPLS [84]. Participants
indicate their agreement with statements by circling ‘true’
or ‘false’, and responses are numerically scored. Higher
scores reflect greater hopelessness or negative expecta-
tions about the future. Internal reliability and test-retest
reliability were both found to be reasonable for the short-
ened version of the HPLS and comparable to the full 17-
item version [85].
Interpersonal Needs Questionnaire
The shortened measure of the original 25-item Interper-
sonal Needs Questionnaire (INQ) contains 15 items
designed to assess the extent to which participants feel
like a burden on the people in their lives (i.e., perceived
burdensomeness) and the extent to which they feel
disconnected from others (i.e., thwarted belongingness).
Statements are rated using a 7-point Likert scale in
terms of how accurately they reflect participants’ recent
feelings. After coding, higher scores reflect greater levels
of thwarted belongingness and perceived burdensome-
ness. The scale was evaluated to have good internal
consistency [86] and construct validity [87].
Acquired Capability for Suicide Scale
The Acquired Capability for Suicide Scale is a five-item
self-report questionnaire that aims to measure an indi-
vidual’s capability to enact lethal self-injury. Questions
assess fear of death and the pain associated with dying.
Items are rated on a scale from 0 (not at all like me) to
4 (very much like me), where higher scores are thought
to be more indicative of one’s capacity for lethal self-
injury. The scale has shown good convergent and dis-
criminant validity [86] and high internal consistency in
previous studies [88].
Insomnia Severity Index
The Insomnia Severity Index is a brief instrument with
seven items that assess the nature, severity and impact
of insomnia upon the responder. Questions assess both
day- and night-time aspects of insomnia over the pre-
ceding 2 weeks and the associated interference with nor-
mal functioning. Items are rated using a 5-point Likert
scale, from 0 (no problem) through to 4 (very severe
problem). The scale has previously been shown to have
excellent internal consistency [89] and good test-retest
reliability, as well as face and content validity [90].
Reduced Morningness-Eveningness Questionnaire
The Reduced Morningness-Eveningness Questionnaire
(MEQr) is a self-report measure consisting of 5 ques-
tions (reduced from the original version containing 19
items) designed to explore participants’ sleep and waking
rhythms and habits. Known as a circadian questionnaire,
the aim of the MEQr is to uncover the individual’s
particular biological rhythm. The stability and external
validity of the reduced questionnaire have been reported
previously [91, 92].
Perceived Sensitivity/Perceived Criticism Scale
The Perceived Sensitivity/Perceived Criticism (PS/PC)
scale is a very brief measure designed to rapidly assess
levels of criticism from relatives as perceived by the
participant [44]. The measure is designed to assess how
critical the respondent perceives their relative to be and
how sensitive the respondent is to this criticism. In the
present study, we will ask specifically about how critical
students perceive their mother and father to be and how
sensitive they are to this criticism. The measure contains
two single items, the first for perceived criticism and the
second for perceived sensitivity to criticism, which are
both rated on a scale from 1 (not at all critical/sensitive)
to 10 (very critical/sensitive indeed). The PS/PC scale
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has been shown to reliably predict outcome for bipolar
disorder [93].
Cortisol and genetics
Cortisol data can be collected via hair strands in class-
rooms, and the procedure is non-invasive, painless, sim-
ple and quick. Saliva samples will also be collected in
classrooms using standardised protocols. These data will
be used for genetic analysis. Both types of biological data
will be collected from students enrolled in the 2016
cohort, pending ethical approval.
Cost-effectiveness outcomes
Trimbos/iMTA questionnaire for Costs associated with
Psychiatric Illness
The Trimbos/iMTA questionnaire for Costs associated
with Psychiatric Illness questionnaire was designed to
assess the costs of psychiatric illness incurred within the
health system, as well as the economic burden associated
with production loss [94]. In the present study, partici-
pants will be asked to recall details about their consulta-
tions with health professionals that have occurred over
the past 6 months, including clinic visits, appointments,
telephone consultations and house calls. The self-report
version of the questionnaire consists of 13 items, each re-
quiring a yes-or-no answer and, if relevant, specification of
the number of times each particular consultation occurred.
Days out of role
This brief questionnaire, administered at 6- and 18-month
follow-up, consists of four questions assessing the number
of days an individual is unable to attend to (or has some
difficulty managing) normal activities (e.g., attending school,
university or work) because of mental health problems.
Questions were adapted from core items from the World
Health Organization Disability Assessment Scale [95] to
focus specifically on mental health.
Assessment of Quality of Life in four dimensions
The Assessment of Quality of Life in four dimensions
(AQoL-4D) [96] is a standardised, self-report instrument
designed to measure health-related quality of life across
five domains: illness, independent living, social relation-
ships, physical senses and psychological well-being. Each
domain consists of three items; however, the illness sub-
scale is not used for scoring purposes and therefore will
not be collected during this trial. Some minor language
adaptations were made to better suit the adolescent
population (e.g., examples of household tasks were chan-
ged from ‘cleaning the house’ and ‘cooking’ to ‘cleaning
your room’ and ‘helping with meals’). These adaptations
were based on language in the AQoL-6D, a 20-item ado-
lescent version of the same scale. The AQoL-4D has dem-
onstrated sound psychometric properties, with reliability
estimates ranging from 0.73 to 0.84 [97]. There is also
some evidence to suggest that the AQoL is more sensitive
than other health-related quality of life instruments to
health states [98].
Process variables
Expectation of success
At the pre-intervention assessment, participants will be
asked a number of questions to determine their expect-
ation of success associated with the intervention they
are about to complete. These questions will assess (1)
beliefs about internet treatments in general and (2) pref-
erence for trial condition. These questions are based on
those used in previous research [99].
Acceptability of the intervention
At the post-intervention assessment, participants will be
asked a range of questions designed to assess the accept-
ability and usability of the intervention they completed.
These questions will measure how understandable and
useful the program was, whether participants perceived
that it affected their behaviour and whether they would
recommend the program to others. Participants will also
be provided with a list of techniques or skills specific to
the program they completed (SPARX-R or lifeSTYLE)
and will be asked which of these skills they have tried
since completing the program and how helpful they
were. These questions are also based on those used in
previous research [99].
Adherence to the intervention
Participants’ adherence to their allocated intervention
will be assessed using automated data collection through
the SPARX-R and lifeSTYLE programs. For each partici-
pant, these data will include total number of visits to the
site, average length of each visit and number of modules
completed.
Reasons for non-adherence
Participants who are designated as non-completers of
their allocated program will be asked to complete a brief
questionnaire assessing their reasons for non-adherence
to the program. These items are adapted from the Inter-
net Intervention Adherence Measure [100], which was
originally developed in the context of a paediatric enco-
presis intervention. The current items are similar to the
adapted version of this measure developed by Farrer and
colleagues [101] for use with an internet-based interven-
tion for depression. Farrer et al.’s version of this measure
includes two additional categories of reasons for non-
adherence which may be relevant to the present trial: (1)
engagement issues and (2) disease-specific issues (per-
taining to depression).
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Parent outcomes
Patient Health Questionnaire-9
The Patient Health Questionnaire-9 (PHQ-9) is a self-
administered nine-item depression screening and diagnos-
tic tool based on DSM-IV criteria. The scale assesses the
nine depression symptom criteria for frequency of occur-
rence during the previous 2 weeks, with scores ranging
from 0 (not at all) to 3 (nearly every day). The psychomet-
ric quality of the PHQ-9 has been established [102].
Generalized Anxiety Disorder 7-item scale
The Generalized Anxiety Disorder 7-item scale is a widely
used self-report anxiety scale which consists of seven items
designed to measure the severity of symptoms of general-
ised anxiety disorder [103]. Participants rate individual
statements on a 4-point frequency scale from 0 (not at all
sure) to 3 (nearly every day) as they pertain to the previous
2 weeks. Individual item scores are summed to produce an
overall score between 0 and 21, with higher scores indica-
tive of greater anxiety. The scale was reported by its devel-
opers to have good reliability in addition to strong criterion,
construct, factorial and procedural validity [103].
Participant risk management protocol
All student participants will be given a contact sheet
with the name and contact details of their school
counsellor, as well as contact information for other
counselling and support services (local and online). In
addition, on each assessment occasion, participants’
responses will be monitored using an automated alert
system that identifies severe mental health concerns,
defined as endorsement of one or more items on the
YRBS. Participants will be asked if they have experi-
enced serious suicidal ideation or engaged in suicidal
behaviour in the previous month. Endorsement of any
item will trigger an alert whereby trial researchers will
be notified immediately, prompting initiation of the
study’s risk management protocol. The researcher will
confidentially communicate the student’s name to the
student’s school counsellor so that the counsellor can
contact the student to offer immediate support. School
counsellors of all participating schools will be briefed
in advance about this risk management procedure.
Students will also be provided with a popup alert via
the online platform indicating that one or more of
their responses suggest they may be distressed and
encouraging them to seek support and/or use the con-
tacts provided on their contact sheet. An email pro-
viding the same message will also be sent to their
nominated email account.
Data collection and management
All self-report data for the present trial will be collected
via the online platform designed for and by the Black Dog
Institute. Data collected routinely through the SPARX-R
program will be passed to the online platform via an appli-
cation programming interface. Data will be coded using a
unique identification code. A list of emails associated with
each identification code will be kept separately from the
outcome database for the sole purpose of matching data
to an individual participant in case of risk. Data will be
stored securely on the university server, and only appro-
priate members of the TriPoD research team will have
access to data collected in the context of this trial. All
research personnel not involved with the day-to-day man-
agement of the trial will remain blinded to intervention
allocation.
Analysis
Primary analyses will be undertaken on an intention to
treat basis, including all participants as randomised,
regardless of treatment actually received. Effectiveness of
SPARX-R will be established using a planned contrast of
change from pre-test to the post-intervention in the
active compared with placebo condition on the MDI
within a mixed-effects model repeated-measures analysis
[104]. School will be included in analyses as a random
effect to evaluate and accommodate clustering effects.
Variables used in determining allocation balance will be
evaluated and retained in analyses where they are signifi-
cant or quasi-significant. An unconstrained variance–co-
variance matrix will model within-individual dependencies.
Transformation of scores, including categorisation, may be
undertaken to meet distributional assumptions and accom-
modate outliers. Contrasts comparing change on the MDI
from pre-test to other occasions of measurement will be
undertaken as secondary analyses.
Models for binary outcomes analogous to the primary
analysis approach will be used to compare the preva-
lence rates (MDD status) and other dichotomous out-
comes between the two treatment arms at the endpoint
and other occasions of measurement. Relative and abso-
lute risk reduction, NNT (see [105]) and other relevant
indices will be calculated for these outcomes and under-
taken separately for participants who did not meet
criteria for caseness at pre-test to assess the effect of the
intervention on incidence. In analyses of scaled second-
ary variables, we will use methods comparable to those
of the primary analysis. Subsidiary complier and related
analyses will estimate the efficacy of SPARX-R in partici-
pants who completed modules from the SPARX-R pro-
gram to produce a clinical impact (estimated to be four
or more modules) [36]. In exploratory analyses, we will
examine the effects of moderators and mediators of
treatment (see [106]).
Interim analysis of outcomes of the 2015 cohort will
be undertaken following the methods described above.
Although the sample available will be of limited size, the
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outcome of this analysis will be used to guide the second
stage of the trial, planned for 2016. Should there be clear
evidence of lack of effect, based point estimates of effect-
iveness and associated confidence intervals, consideration
may be given to abandoning second-stage recruitment or
seeking possible modifications of the intervention.
Dissemination
This trial is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12614000316606). All
protocol amendments will be listed on this registry. A
lay-language summary of key findings will be provided
to participating schools at the conclusion of the trial,
and results will be disseminated to the scientific commu-
nity via publications and conference presentations. This
trial will be reported in accordance with the World
Health Organisation Statement on Public Disclosure of
Clinical Trial Results [107]. No restrictions have been
imposed on the dissemination of the data by funders or
any other party.
Discussion
In the present trial, we will investigate the effectiveness
of the SPARX-R intervention in the prevention of de-
pression in young people. To our knowledge, this is the
first trial of a universal prevention intervention delivered
to school students in advance of a specific, significant
exogenous stressor. Should it be shown to be effective,
SPARX-R may offer an accessible, cost-effective, scalable
and youth-friendly option for delivering a wide-scale
prevention program in schools.
Although there is evidence to support the use of SPARX
as a treatment for depression, its use as a preventive inter-
vention has not yet been evaluated. Further, although
previous qualitative studies have found the intervention to
be feasible and acceptable in other samples (including
students in alternative education and youth in rural
Australia), the feasibility of this program in a school con-
text and, in particular, with academically selective students
is not known. In addition to acceptability information
collected from students, staff feedback questionnaires will
be provided to teachers who helped facilitate the trial to
determine their perspectives on the feasibility of the
intervention.
The focus on selective high schools in the first stage of
this study has both advantages and limitations. In terms
of advantages, the nature of the sample ensures that we
are delivering the intervention to young people who may
be particularly at risk of developing mental health diffi-
culties caused by increased rates of stress, achievement
orientation and perfectionism [47–49]. In contrast, this
may limit the generalizability of our findings, as selective
schools provide a unique sample of youth. Indeed, one
may argue that the first year of the trial is in fact a
universal intervention within a selective (high-risk) sam-
ple. Nevertheless, we intend to continue this study in
non-selective schools following the initial stage of the
trial, which will allow for comparison across different
school types and students.
Trial status
Twenty-three selective or partially selective high schools
were approached to participate in the trial between
August and October, 2014. Fourteen of the schools
agreed to participate; however, four schools subsequently
withdrew from the study. The final sample for the 2015
cohort consisted of two partially selective and eight
selective government secondary schools. The 2015 co-
hort of schools completed their baseline assessments in
February, 2015, followed by their respective online pro-
grams. All post-intervention assessments were com-
pleted by April, 2015 and six-month follow-up data was
collected in August, 2015. Educational outcomes (HSC
results) and 18 month follow-up data will be collected in
2016 for this cohort.
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